Announced Wed, 19 Aug · 20:59 IST
Bafna Pharma FY26 Annual Report: Net Profit jumps 167% to Rs.111 mn
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.0%1-day move
₹242.55
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-0.0—————————
Up moveDown movePending
AI summary
Bafna Pharma FY26 results: Total income Rs.1,506 mn (+3.26%), exports at Rs.958 mn (+31.29%). EBITDA Rs.207 mn (+48.74%) with margin improving to 13.75% from 9.54%, advancing toward 15% target. Net profit Rs.111 mn (+167%) and EPS at Rs.4.69. Filed 51 new product registrations across 9 countries, plans 6-8 new dossiers annually. ICRA upgraded credit outlook from stable to positive. 31st AGM set for September 11, 2026 via video conferencing.
Likely market impact
Strong profit growth and margin expansion backed by exports and credit rating upgrade. Positive signal for investor sentiment and future growth.